Glucotrack (Nasdaq:GCTK) announced that it plans to effect a 1-for-60 reverse stock split of its issued and outstanding common stock. Rutherford, New Jersey-based Glucotrack — maker of a long-term implantable continuous blood glucose monitor (CBGM) — intends for the split to go into effect when the market opens on Monday, June 16, 2025. Under the terms […]
Patient Monitoring
Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
Medtronic (NYSE:MDT) announced today that it selected “MiniMed” as the name for its Diabetes unit following its planned separation. The medtech giant announced last month that it planned to separate the Diabetes unit. The move sought to create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. At the same time, […]
Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
Insulet (Nasdaq:PODD) today announced the compatibility of its Omnipod 5 App for iPhone with Dexcom G7 continuous glucose monitor (CGM). The latest integration combines the benefits of the companies’ latest technologies, all conveniently controlled from an iPhone. Omnipod 5, the first FDA-cleared tubeless automated insulin delivery system, communicates with a CGM, such as G7. It […]
Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
Tandem Diabetes Care (Nasdaq:TNDM) today announced an agreement to develop and commercialize diabetes tech with Abbott (NYSE:ABT). San Diego–based Tandem said it agreed to combine its insulin delivery systems with Abbott’s future dual glucose-ketone sensor. The companies aim to provide more options for people to manage their diabetes. This marks the second recent collaboration announcement […]
Roche, IBM collab on predictive AI for CGM tech
Roche and IBM recently announced the development of an AI-enabled solution to predict glucose levels through continuous glucose monitors (CGMs). Together, the companies developed the AI-based Accu-Chek SmartGuide Predict app. They said in a news release that they launched the solution in Switzerland earlier this year. Roche first unveiled its Accu-Chek SmartGuide in an event at […]
Senseonics closes public offering, private placement with Abbott
Senseonics (NYSE:SENS) announced that it closed its previously announced public offering and private placement with Abbott. Last week, the long-term continuous glucose monitor maker said it commenced an underwritten public offering of common stock worth $50 million. At the same time, it entered into a securities purchase agreement with another CGM maker — Abbott. Under […]
Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
Sequel Med Tech announced today that it agreed to integrate its twiist automated insulin delivery system with a future Abbott sensor. The companies agreed to pair twiist, powered by Tidepool, with Abbott‘s glucose-ketone sensor, currently under development. Sequel said the agreement aims to improve outcomes for people with type 1 diabetes. It adds ketone sensing capabilities […]
Medtronic to separate Diabetes business unit
Medtronic (NYSE:MDT) announced today that it intends to separate its Diabetes business into a new standalone company. The medtech giant said the strategic decision can create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. At the same time, it creates an independent, scaled leader in diabetes. The new company — […]
Senseonics opens $50M public offering, $25M private placement with Abbott
Senseonics (NYSE:SENS) announced today that it commenced an underwritten public offering of common stock worth $50 million. The long-term implantable continuous glucose monitor (CGM) maker expects to grant underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of stock offered in the public offering. All shares to be […]
Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
Abbott (NYSE:ABT) today announced results from real-world studies demonstrating benefits with its FreeStyle Libre continuous glucose monitoring (CGM) technology. Results from the REFLECT studies show that Libre CGM is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes. Data demonstrated that CGM can help lessen the severity […]
